Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Kalvista Pharmaceuticals Inc KALV

Healthcare Biotechnology
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:KALV)

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 5 days ago

KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year

Business Wire 6 days ago

KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors

Business Wire April 22, 2024

KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference

Business Wire April 3, 2024

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 2, 2024

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

Business Wire March 18, 2024

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

Business Wire March 12, 2024

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

Business Wire March 11, 2024

KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

Business Wire March 8, 2024
View More News ››

Opinion & Analysis (NDAQ:KALV)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:KALV)

Insiders Buying Monro And 3 Other Stocks | Benzinga

JUST IN: $KALV Insiders Buying Monro And 3 Other Stocks | BenzingaAlthough U.S. stocks closed higher on Thursday, there were a few...
whytestocks - February 9, 2024
View more Bullboard ››

Vertiqal Studios Corp.

Vertiqal Studios Corp.

Vertiqal Studios is a leading global digital media entertainment, production, and distribution company redefining the ...
View More »